多西紫杉醇联合奈达铂治疗转移非小细胞肺癌的疗效及耐受性临床研究  

Clinical research of the curative effect and security of docetaxel combined with nedaplatin in the treatment of metastatic non-small cell lung cancer

作　　者：盘玉飞[1] 吴冬梅[1] 梁百晖[1] 李明[1] 林高娟[1] 

机构地区：[1]广西壮族自治区第二人民医院肿瘤科,广西桂林541002

出　　处：《中国现代医药杂志》2016年第2期17-20,共4页Modern Medicine Journal of China

摘　　要：目的评估多西紫杉醇联合奈达铂化疗方案对转移非小细胞肺癌(NSCLC)患者的疗效与安全性。方法选择我院2013年3月~2015年3月收治的ⅢB(非局部晚期)或Ⅳ期转移NSCLC患者44例,化疗第1天时使用多西紫杉醇(60mg/m^2)及奈达铂(80mg/m^2),每3~4周重复1次,共4个疗程,评估患者肿瘤缓解情况及不良反应。结果 44例患者共接受了140个疗程的治疗,缓解率为50.0%,疾病控制率为75.0%。中位存活时间为13.0个月,无进展生存时间为7.4个月。非血液系统毒性程度较轻。结论多西紫杉醇联合奈达铂方案治疗转移非小细胞肺癌,患者耐受性较好,有一定疗效,在鳞癌患者中尤为显著。Objective To evaluate the curative effect and tolerability of docetaxel combined with nedaplatin in the treat- ment of metastatic non-small cell lung cancer（NSCLC）. Methods 44 patients with metastatic non-small cell lung cancer（non locally advanced m B or IV ） were selected from Mar 2013 to Mar 2015 in our hospital,all the patients were treated with doc- etaxel（60mg/m2） and nedaplatin （80mg/m2） on the first day, once time every 3-4 weeks for 4 courses, evaluated the tumor re- sponse and adverse reactions of the patients. Results Patients received 140 courses of treatment, tumor mitigative response rate was 50.0%, disease control rate was 75.0%, median survival time was 13.0 months, progression-free survival was 7.4 months. The degree of non-hematological toxicity was relatively less. Conclusion Docetaxel combined with nedaplatin treating for metastatic non-small cell lung cancer has excellent tolerability and certain curative effect, especially for squamous cell carcinoma.

关 键 词：多西紫杉醇 奈达铂 非小细胞肺癌 鳞状细胞癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]